Open Access


Read more
image01

Online Manuscript Submission


Read more
image01

Submitted Manuscript Trail


Read more
image01

Online Payment


Read more
image01

Online Subscription


Read more
image01

Email Alert



Read more
image01

Original Research Article | OPEN ACCESS

Adiponectin regulates the malignant biological behavior of endometrial cancer cells via AMPK/mTOR signal pathway

Li Jin1, Xiumei Feng2, Dan Luo2

1Department of Gynecology, Jingmen No. 1 People's Hospital, Jingmen; 2Department of Gynecology, Jingmen No. 2 People's Hospital, Jingmen, PR China.

For correspondence:-    

Accepted: 24 April 2021        Published: 31 May 2021

Citation: Jin L, Feng X, Luo D. Adiponectin regulates the malignant biological behavior of endometrial cancer cells via AMPK/mTOR signal pathway. Trop J Pharm Res 2021; 20(5):933-938 doi: 10.4314/tjpr.v20i5.7

© 2021 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To study the mechanism by which adiponectin regulates the malignant biological behavior of endometrial cancer cells.
Methods: RL95-2 cells were cultured and re-suspended in complete medium. A preliminary study showed that adiponectin (20 μg/mL) has the most inhibitory effect on cellular proliferation. The cells were divided into control group, 20 μg/mL adiponectin group, and 20 μg/mL adiponectin + 10 μmol/L AMPK inhibitor group, with 4 repeat wells set up for each group. Cell proliferation, apoptosis, invasion and migration ability, as well as the expression levels of MMP-9, Bcl-2, p-AMPK, p-mTOR and p-4ebp1 were determined using standard procedures.
Results: Cell proliferation was significantly higher in the 20 μg/mL adiponectin group than in the 10 μg/mL adiponectin group (p < 0.05). Relative to the control group, apoptosis and p-AMPK expression level in the 10 μg/mL adiponectin group increased, while cell invasion and migratory potential, as well as expression levels of MMP-9, Bcl-2, p-mTOR and p-4ebp1 declined significantly (p < 0.05). The apoptosis and expression level of p-AMPK in the 20 μg/mL adiponectin + 10 μmol/L AMPK inhibitor group decreased, while cell invasion, migratory ability, and amounts of MMP-9, Bcl-2, p-mTOR and p-4ebp1 were elevated, relative to the 20 μg/mL adiponectin group (p < 0.05).
Conclusion: Adiponectin promotes apoptosis of endometrial cancer cells via AMPK/mTOR signaling pathway, and inhibits cell proliferation, invasion and migration. Thus, adiponectin has the potential to exert anti-tumor effect in humans

Keywords: Adiponectin, AMPK/mTOR, Endometrial cancer, Biological behavior, Mechanism

Impact Factor
Thompson Reuters (ISI): 0.6 (2023)
H-5 index (Google Scholar): 49 (2023)

Article Tools

Share this article with



Article status: Free
Fulltext in PDF
Similar articles in Google
Similar article in this Journal:

Archives

2024; 23: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10
2023; 22: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2022; 21: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2021; 20: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2020; 19: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2019; 18: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2018; 17: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2017; 16: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2016; 15: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2015; 14: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2014; 13: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2013; 12: 
1,   2,   3,   4,   5,   6
2012; 11: 
1,   2,   3,   4,   5,   6
2011; 10: 
1,   2,   3,   4,   5,   6
2010; 9: 
1,   2,   3,   4,   5,   6
2009; 8: 
1,   2,   3,   4,   5,   6
2008; 7: 
1,   2,   3,   4
2007; 6: 
1,   2,   3,   4
2006; 5: 
1,   2
2005; 4: 
1,   2
2004; 3: 
1
2003; 2: 
1,   2
2002; 1: 
1,   2

News Updates